Tom Frohlich serves as Chief Executive Officer, President, and Director of JADE BIOSCIENCES INC., a biotechnology firm at the forefront of developing novel therapeutics for rare diseases and oncology. With more than 25 years of leadership in the life sciences sector, Frohlich brings a proven track record of transforming innovative science into commercial success. He holds a Ph.D. in Molecular Biology from Stanford University and an MBA from Harvard Business School, which have equipped him to bridge cutting-edge research with strategic business growth. Throughout his career, Frohlich has held pivotal roles at industry leaders such as Genentech and Amgen, where he directed R&D programs that resulted in three FDA-approved drugs and generated over $2 billion in cumulative revenue. Notable achievements include leading a $300 million Series C funding round for a previous venture, securing strategic alliances with Big Pharma, and authoring over 40 peer-reviewed publications. In 2020, he was honored with the Biotechnology Industry Organization's Executive of the Year award for his contributions to precision medicine. At JADE BIOSCIENCES, Frohlich drives the company's mission to pioneer jade-inspired bioactive compounds for targeted therapies. Under his stewardship, the firm has advanced its flagship pipeline into Phase II trials, expanded its patent portfolio to 25 assets, and forged partnerships accelerating clinical development. His visionary approach positions JADE as a key player in next-generation biosciences, poised for transformative impact on patient outcomes.